Higher Serum Selenoprotein P Level as a Novel Inductor of Metabolic Complications in Psoriasis.
antipsoriatic treatment
cardiometabolic diseases
hepatokines
psoriasis
selenoprotein P
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
28 Jun 2020
28 Jun 2020
Historique:
received:
08
06
2020
revised:
19
06
2020
accepted:
22
06
2020
entrez:
2
7
2020
pubmed:
2
7
2020
medline:
20
3
2021
Statut:
epublish
Résumé
Selenoprotein P (SeP), a member of hepatokines, is involved in the development of various metabolic diseases closely related to psoriasis, but it has not been explored in that dermatosis so far. The study aimed to evaluate the clinical value of serum SeP concentrations in patients with psoriasis and its interplay between disease activity, metabolic or inflammatory parameters and systemic therapy. The study included thirty-three patients with flared plaque-type psoriasis and fifteen healthy volunteers. Blood samples were collected before and after three months of treatment with methotrexate or acitretin. Serum SeP levels were evaluated using the immune-enzymatic method. SeP concentration was significantly higher in patients with psoriasis than in the controls (p < 0.05). Further, in patients with severe psoriasis, SeP was significantly increased, compared with the healthy volunteers before treatment, and significantly decreased after (p < 0.05, p = 0.041, respectively). SeP positively correlated with C-reactive protein and platelets and negatively with red blood counts (p = 0.008, p = 0.013, p = 0.022, respectively). Therapy resulted in a significant decrease in SeP level. Selenoprotein P may be a novel indicator of inflammation and the metabolic complications development in psoriatics, especially with severe form or with concomitant obesity. Classic systemic therapy has a beneficial effect on reducing the risk of comorbidities by inhibiting SeP.
Identifiants
pubmed: 32605214
pii: ijms21134594
doi: 10.3390/ijms21134594
pmc: PMC7370132
pii:
doi:
Substances chimiques
Biomarkers
0
Selenoprotein P
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Uniwersytet Medyczny w Białymstoku
ID : R-I-002/429/2017
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
J Clin Endocrinol Metab. 2011 Aug;96(8):E1325-9
pubmed: 21677040
Nutrition. 2003 Apr;19(4):301-4
pubmed: 12679161
Eur Rev Med Pharmacol Sci. 2018 Dec;22(23):8537-8551
pubmed: 30556896
J Biol Chem. 2017 Jun 30;292(26):10791-10800
pubmed: 28465347
Arch Dermatol Res. 2017 Jul;309(5):371-380
pubmed: 28585093
Nutrition. 2006 Sep;22(9):860-4
pubmed: 16829029
Genes Nutr. 2018 Jul 13;13:20
pubmed: 30008961
Int J Obes (Lond). 2014 Dec;38(12):1497-502
pubmed: 24638201
J Am Acad Dermatol. 2019 Apr;80(4):1073-1113
pubmed: 30772097
Gynecol Endocrinol. 2015;31(11):874-6
pubmed: 26514640
Biol Chem. 2007 Oct;388(10):1035-41
pubmed: 17937617
Biol Trace Elem Res. 2014 Dec;161(3):231-45
pubmed: 24974905
Ann Clin Biochem. 1989 Jan;26 ( Pt 1):83-8
pubmed: 2735752
J Am Acad Dermatol. 2017 Mar;76(3):377-390
pubmed: 28212759
J Cachexia Sarcopenia Muscle. 2015 Dec;6(4):358-64
pubmed: 26673741
Nutrients. 2015 May 15;7(5):3621-51
pubmed: 25988760
Antioxid Redox Signal. 2012 Apr 1;16(7):705-43
pubmed: 21955027
Trends Cardiovasc Med. 2004 Oct;14(7):273-81
pubmed: 15542379
Biochim Biophys Acta. 2009 Nov;1790(11):1441-7
pubmed: 19345254
J Clin Invest. 2010 Dec;120(12):4220-35
pubmed: 21084748
Nutrients. 2016 Feb 06;8(2):80
pubmed: 26861388
Free Radic Biol Med. 2018 Nov 1;127:198-205
pubmed: 29572096
Cancer Epidemiol Biomarkers Prev. 2009 Sep;18(9):2386-90
pubmed: 19690186
Clin Nutr. 2014 Jun;33(3):399-405
pubmed: 24120032
Redox Biol. 2017 Apr;11:403-414
pubmed: 28064116
An Bras Dermatol. 2013 Nov-Dec;88(6):1029-35
pubmed: 24474126
Exp Dermatol. 2012 Jan;21(1):43-7
pubmed: 22151390
J Biol Chem. 2014 Jan 3;289(1):335-45
pubmed: 24257750
J Cell Mol Med. 2013 Mar;17(3):350-5
pubmed: 23402643
Clin Dermatol. 2018 Jan - Feb;36(1):21-28
pubmed: 29241748
Curr Drug Targets. 2013 Jun 1;14(6):708-22
pubmed: 23531113
Obesity (Silver Spring). 2017 Jun;25(6):1128-1135
pubmed: 28474510
Obes Res Clin Pract. 2017 Mar - Apr;11(2):227-232
pubmed: 27524654
Diabetologia. 2014 Sep;57(9):1968-76
pubmed: 24989996
J Clin Med. 2019 Dec 13;8(12):
pubmed: 31847236
Biochem Biophys Res Commun. 2009 Sep 11;387(1):158-63
pubmed: 19576170
Open Access Maced J Med Sci. 2019 Jan 27;7(2):237-242
pubmed: 30745969
J Eur Acad Dermatol Venereol. 2012 Mar;26(3):302-7
pubmed: 21418334
Nutr Res. 2009 Feb;29(2):94-9
pubmed: 19285599
Acta Biochim Pol. 2016;63(3):459-67
pubmed: 27262842
Biol Pharm Bull. 2020;43(3):366-374
pubmed: 32115498
Breast Cancer Res Treat. 2006 Jun;97(3):225-30
pubmed: 16791483
Einstein (Sao Paulo). 2012 Jan-Mar;10(1):44-52
pubmed: 23045825
PLoS One. 2012;7(4):e34952
pubmed: 22496878
Dermatol Clin. 2015 Jan;33(1):41-55
pubmed: 25412782
Nutrients. 2019 Aug 09;11(8):
pubmed: 31404994
Exp Clin Endocrinol Diabetes. 2019 Oct;127(9):598-602
pubmed: 30625508
Antioxidants (Basel). 2018 May 14;7(5):
pubmed: 29758013
J Eur Acad Dermatol Venereol. 2016 Feb;30(2):282-7
pubmed: 26537011
Cell Metab. 2010 Nov 3;12(5):483-95
pubmed: 21035759
Nat Rev Endocrinol. 2013 Mar;9(3):144-52
pubmed: 23337953
Nat Med. 2017 Apr;23(4):508-516
pubmed: 28263310
Blood. 2018 Jun 7;131(23):2568-2580
pubmed: 29615406
Int J Cancer. 2015 Mar 1;136(5):1149-61
pubmed: 25042282
Biochim Biophys Acta. 2009 Nov;1790(11):1424-8
pubmed: 19477234
Physiology (Bethesda). 2006 Oct;21:307-15
pubmed: 16990451
Diabetes Metab J. 2013 Feb;37(1):63-71
pubmed: 23439771
EMBO J. 2000 Dec 15;19(24):6882-90
pubmed: 11118223
Nat Commun. 2017 Nov 21;8(1):1658
pubmed: 29162828
Free Radic Biol Med. 2018 Nov 1;127:165-171
pubmed: 29719207